19:41 , Mar 14, 2019 |  BC Week In Review  |  Clinical News

Adare’s APT-1011 meets in Phase IIb for eosinophilic esophagitis

Adare said it plans to start a Phase III program next half of APT-1011 (AdvaTab Fluticasone) to treat eosinophilic esophagitis after reporting that the product met the primary endpoint in the Phase IIb FLUTE trial...
07:00 , May 18, 2015 |  BC Week In Review  |  Company News

Actavis, TPG Capital deal

Actavis completed the divestiture of its Aptalis Pharmaceutical Technologies subsidiary to private investment firm TPG for an undisclosed sum. Aptalis said that its new name is Adare Pharmaceuticals (see BioCentury, Feb. 16). Actavis Group ,...